This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Thank you. Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc., third quarter 2026 earnings results conference call. Please note this event is being recorded. After the speaker's prepared remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by 1 on your telephone keypad. If you would like to withdraw your question, please press star then number 2 on your telephone keypad. It is now my pleasure to turn the conference over to Irina Koffler.
Thank you, Keith. Welcome to ANI Pharmaceuticals' third quarter 2026 earnings results call. This is Irina Koffler, Investor Relations for ANI. With me on today's call are Nikhil Lalwani, President and Chief Executive Officer, Stephen Carey, Senior Vice President and Chief Financial Officer, Chris Muth, Senior Vice President and Head of ANI's Rare Disease Business, and Mary Pao, Chief Medical Officer. Earlier this morning on November 5th, 2026, we released our results in the third quarter 2026 via a press release that is available on our website. This call is also available via webcast and is accompanied by a slide deck that can be accessed by going to the events section of the investors page of our website. During this call, we will also be discussing the terms and conditions of ANI's offer to acquire outstanding securities of Aegida Therapeutics, which ANI announced this morning. Please refer to the transaction website at www.biopharma-offer.com and the 8K filed by A&I this morning that include further information about the offer, including important considerations for holders of Aegida securities in the United States. Before we begin, I would like to remind you that we will be making forward-looking statements and discussing certain non-GAAP measures. Forward-looking statements are subject to substantial risks and uncertainties, speak only to the call's original date, and we take no obligation to update or revise any of the statements. During this call, we will also refer to certain non-GAAP financial measures to describe our performance and have provided a reconciliation to the most directly comparable GAAP financial measures within the materials that accompany this call. The archived webcast will be available for one year on our website, anifarmaceuticals.com. Okay, turning to the agenda for today's call, Nikhil will provide an overview of our corporate strategy and Q3 performance, followed by an overview of our offer to acquire Ajita Therapeutics. Mary will dive into more detail on MCTA deficiency and MCTA's mechanism of action. Chris will discuss the commercial opportunity for MCTA and will also provide an update on our rare disease business. Lastly, Steve will discuss our Q3 financial results and 2026 guidance. And with that, I'll turn the call over to Nikhil Lalwani.
Thank you, Irina. Good morning, everyone, and thank you for joining us. We are now on slide seven. At the start of 2026, we set out three strategic priorities designed to position ANI for long-term growth. These include, first, accelerating ANI's transformation into a leading rare disease company, Second, driving continued excellence in generics R&D and operations. And third, executing a disciplined capital allocation strategy. At ANI, we take pride in our virtual cycle of growth in which our generics and brands business generate meaningful cash flows to support our rare disease business. We are making meaningful progress against each of these priorities, including with today's offer to acquire Aegidus Therapeutics. Before we dive into the details regarding the EGIDIS offer, I want to talk you through our third quarter results at a high level and our updated guidance. Turning to slide 8, for the third quarter, we generated $290.8 million of total revenues for the overall business, up 28% year-over-year, and adjusted EBITDA of $83.3 million, up 40% year-over-year. Rare Disease Net Revenues grew 36% year-over-year, and we saw continued growth in generics up 11% year-over-year. Moving to slide nine, while we delivered strong overall results on the top and bottom line, I want to address our cortofin performance. We've been clear that our goal for cortofin is to maximize its multi-year growth opportunity by building on the momentum in our existing specialties and by expanding our organization to capture the sizable and unique opportunity in acute gouty arthritis flares. In the third quarter, cortofan gel net revenues came in lighter than we expected when we outlined guidance last quarter at 138.7 million. This was primarily driven by two factors. First, for the gout expansion team, we had strong demand generation in the third quarter with a large funnel of new patient cases which doubled compared to the second quarter, highlighting physician interest and a large volume of appropriate patients. The significant volume of new gout cases put pressure on our specialty pharmacy network capacity, impacting the amount of cases that were processed for gout and also for our existing specialties of neurology, nephrology, rheumatology, ophthalmology, and pulmonology. Secondly, we increased our new prescriber base in the gout expansion by 67% compared to prior quarter. The primary care and podiatrist offices naive to ACTH are ramping up their capabilities in navigating the cortofan enrollment to fulfillment process. This ramp has taken a bit longer than we had anticipated. This dynamic coupled with the impact to our specialty pharmacy network capacity that I just mentioned resulted in longer than expected conversion of new gout cases to patients on therapy. Chris will walk you through the significant steps we have already taken to address these dynamics. This is a key priority for us in the near term and we are already seeing improvements in getting both gout and existing specialty patients onto therapy. That said, we are revising our 2026 cortofan gel net revenue guidance to 480 million to 500 million compared to 520 to 540 million previously. Importantly, this represents year-over-year growth of over 40% at the midpoint on this revised guidance range. And nothing we have seen changes our conviction in the gout opportunity or in the strong multi-year growth potential of cortofin across indications. With respect to Illuvian, we demonstrated strong year-over-year revenue growth of 34%. We plan to leverage the new synchronicity study data presented at AAO in October with a focus on the retina specialist community to return alluvium to growth across global markets. With three quarters under our belt, we are also tightening the guidance ranges for total company net revenue, adjusted non-gap EBITDA, and raising adjusted non-gap EPS. Our 2026 guidance reflects significant top and bottom line growth and the strength and diversification of our business, in particular, the continued outperformance of our genetics business. Steve will walk you through the details later. As you can see on slide 10, year to date we have launched 16 generics. We also continue to hold the number two position in overall CGT filings and approvals. We are proud of our team's operational execution as it was able to seize multiple opportunities and benefit from strong market demand to deliver another outstanding quarter with generics revenue of $104.5 million, up 11% year-over-year. In terms of our third priority, discipline capital allocation, we are continuing to invest in organic growth, most visibly in the gout expansion, and continuing to put a high single-digit percentage of generics revenues into generics R&D. We also repurchased $20 million in shares under the share repurchase program that was authorized by our board in May. reflecting our confidence in ANI's future. Steve will provide more details. And finally, today we also announced the offer to acquire Aegidus Therapeutics. Turning to slide 11. Throughout the year, we have said that we are actively evaluating opportunities to expand our rare disease business with a focus on attractive commercial stage or newer commercial assets with durable IP that leverage our organizational capabilities. Aegidus meets each of these objectives. First and foremost, this transaction builds on our mission of serving patients, improving lives, which is really at the core of everything we do at ANI. We have followed the AGITAS team closely, and we have been deeply impressed by their commitment to patients with MCT8 deficiency and to the families who care for them. This is a devastating condition. Children are born with it, families provide around-the-clock care, and until very recently, there was no approved treatment. As we bring Aegidus into ANI, our commitment is to honor that work to ensure that the patients and caregivers have the support they need to access the first and only approved treatment for MCTA deficiency. Second, it expands the scope and scale of our rare disease business, broadening our commercial footprint into an additional rare disease call point with a product that has the potential to generate annual peak sales of over $300 million in its approved indication. Third, it has a new durable goat driver, MCTAID. MCTAID is the first and only approved treatment in the EU and U.S. for peripheral thyrotoxicosis associated with MCTA deficiency. This is a rare disease, impacting more than 1,000 patients in the U.S. alone, and we will endeavor to facilitate patient diagnosis and bring this therapeutic to the appropriate patients in need. Fourth, it leverages our resources and existing rare disease expertise and infrastructure to support MCIT's commercial launch. Our commercial organization brings deep rare disease experience along with patient support, market access, and specialty pharmacy capabilities that we have built over the past five years with Cotrofen and Alluvian. We believe we can leverage our resources and capabilities to maximize the reach and impact of MCITATE in one of the most underserved patient communities. Fifth, it strengthens our R&D capabilities, adding additional development and regulatory expertise in rare disease, along with a potential pipeline opportunity for MCITATE in RTH beta, a separate rare indication. And finally, It diversifies our revenue base and enhances our long-term growth and profitability profile. Turning to slide 12, MC-8 represents an ideal product to add to our portfolio. Mary will speak to the disease in more detail shortly. MC-8 was approved in Europe in February 2025 and in the U.S. in September 2026. MC-8 became commercially available in the U.S. last week on October 27th. We estimate that approximately 1 in 70,000 males are impacted by MCT8 deficiency globally. Today, more than 100 U.S. patients have been genetically confirmed and approximately 60 U.S. patients are already receiving MCT8 through an expanded access program or EAP. This EAP gives us a clear starting point for the U.S. launch with a significant opportunity to identify, diagnose, and treat additional appropriate patients over time. MCAT has durable growth runway supported by new chemical entity exclusivity, orphan drug exclusivity in both the US and the EU, and an orange book listed patent extending into mid-2045. We believe we have put forward an attractive offer that allows Aegidus shareholders to realize the forward-looking value of MCAT, and we are pleased with the unanimous support we have received from the Aegidus Board of Directors and significant shareholders controlling approximately 42% of shares. Site 13 outlines the financial terms. We are offering to acquire Aegidus for a total equity consideration of $560 million. This represents an enterprise value of approximately $434 million net of the $95 million in cash proceeds that Aegidus has agreed to receive from its sale of its pediatric rare disease priority review voucher, which was announced yesterday. This is an all-cash deal, and we will fund it through a combination of existing cash on hand and up to $300 million in debt surrounded by new committed bridge financing facility from JPMorgan. Upon closing of the deal, we expect trailing 12-month pro forma net leverage to be approximately 2.7x. From a financial perspective, the deal enhances our growth profile. With MCIT in the early launch phase, we believe we can maximize its reach by leveraging our resources and rare disease infrastructure. That said, we do expect it to be diluted to adjusted non-GAAP EPS in year one, driven by investments to support the US commercial launch. We expect the deal to close in late 26 or early 27, subject to customary closing conditions. And with that, I'll turn the call over to Dr. Mary Pao are Chief Medical Officer to provide an overview of MCT8 deficiency. Mary?
You're reading a preview of the ANIP Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing